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Abstract
Infection of glial cells by the human polyomavirus JC (JCV) causes progressive multifocal leukoencephalopathy (PML). JCV
Encephalopathy (JCVE) is a newly identified disease characterized by JCV infection of cortical pyramidal neurons. The virus
JCVCPN associated with JCVE contains a unique 143 base pair deletion in the agnogene. Contrary to most JCV brain isolates,
JCVCPN has an archetype-like regulatory region (RR) usually found in kidney strains. This provided us with the unique
opportunity to determine for the first time how each of these regions contributed to the phenotype of JCVCPN. We
characterized the replication of JCVCPN compared to the prototype virus JCVMad-1 in kidney, glial and neuronal cell lines. We
found that JCVCPN is capable of replicating viral DNA in all cell lines tested, but is unable to establish persistent infection
seen with JCVMad-1. JCVCPN does not have an increased ability to replicate in the neuronal cell line tested. To determine
whether this phenotype results from the archetype-like RR or the agnogene deletion, we generated chimeric viruses
between JCVCPN of JCVMad-1. We found that the deletion in the agnogene is the predominant cause of the inability of the
virus to maintain a persistent infection, with the introduction of a full length agnogene, either with or without agnoprotein
expression, rescues the replication of JCVCPN. Studying this naturally occurring pathogenic variant of JCV provides a valuable
tool for understanding the functions of the agnogene and RR form in JCV replication.
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Introduction
The human polyomavirus JC (JCV) has a circular double
stranded DNA genome which can be divided into 3 regions. The
early coding region encodes the regulatory proteins small t antigen
and large T antigen (T Ag). The late coding region encodes the
VP1, VP2 and VP3 structural proteins, and the agnoprotein [1].
The regulatory region (RR) contains the origin of replication, as
well as the early and late promoters [2,3]. While the coding
regions are well conserved, the RR is hypervariable, with different
sequences being isolated from individuals [1]. Archetype RR,
which has one 98-bp element and contains a 23-bp and a 66-bp
insert, is generally found in the kidneys or urine of healthy and
immunosuppressed individuals [4]. RRs from the brain or CSF of
PML patients are generally of the rearranged type, containing two
98-bp tandem repeats with additional mutations, insertions and
deletions [1,2].
JCV is the etiological agent of Progressive Multifocal Leukoen-
cephalopathy (PML), an often fatal demyelinating disease caused
by lytic infection of oligodendrocytes by the virus [5]. Infection
with JCV is widespread in the population, but remains asymp-
tomatic in healthy people [6,7]. Development of PML is associated
with immune suppression, such as in patients with AIDS [8],
organ transplants [9] or hematological malignancies [10]. We
have identified two additional syndromes caused by JCV infection
in the brain, JCV Granule Cell Neuronopathy (JCV GCN)
[11,12,13] and JCV Encephalopathy (JCVE) [14]. The viruses
isolated from patients with these syndromes contain previously
unreported unique mutations. JCV GCN is associated with
deletions in the C-terminus of the VP1 protein [15,16] and JCVE
with a deletion in the agnogene [17]. These naturally occurring
pathogenic variants provide a unique tool for studying the basic
biology of JCV replication and pathogenesis.
JCVE was described in an HIV-negative patient with a history
of lung cancer treated with chemotherapy, who presented with
cortical lesions, aphasia and progressive cognitive decline. Post-
mortem analysis of the brain showed cortical lesions with
productive infection of cortical pyramidal neurons [14]. Isolation
and sequencing of the JCV DNA present in the brain of this
patient identified a virus with an archetype-like RR and a 143 base
pair deletion in the agnogene [17]. This virus was named JCV
Cortical Pyramidal Neuron 1 (JCVCPN1). The deleted agnogene
encodes a 10 amino acid truncated peptide. Further analysis found
that multiple forms of JCVCPN were present, and that these strains
co-existed with a virus containing a full length agnogene.
Immunostaining analysis indicated that the majority of the cortical
cells infected with JCV contained the truncated form of the
agnoprotein [17].
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JCV agnoprotein is a highly basic, 71 amino acid, non-essential
protein that is expressed late in infection, but not incorporated into
virions [18]. It is primarily expressed in the cytoplasm, particularly
in the perinuclear region, with a small amount found in the
nucleus [19]. Agnoprotein has been shown to form homodimers
and oligimers [20]. Agnoprotein contains 3 phosphorylation sites,
which can be phosphorylated by protein kinase C [21] and
dephosphorylated by protein phosphatase 2A [22]. The phos-
phorylation state may impact agnoprotein localization [19].
Agnoprotein has been shown to bind to T Ag, down regulating
DNA replication [23] and enhancing T Ag origin binding [24].
Agnoprotein may also influence viral gene expression and splicing
of viral transcripts [25]. Loss of agnoprotein expression has been
associated with loss of early and late mRNA expression [19].
Agnoprotein has also been shown to suppress activity of the late
promoter [23], and to interact with the transcription factor YB-1,
inhibiting its ability to activate the early and late promoters [26].
Prevention of agnoprotein expression also has been shown to result
in decreased levels of T Ag and VP1 protein expression [27].
Viruses lacking agnoprotein are less efficient at packaging DNA
and virion formation, with infected cells releasing empty particles
[27,28]. The agnoprotein may also function as a viroporin, aiding
in the release of virions from infected cells [29]. These studies have
added to our knowledge of agnoprotein function in recent years,
but the exact mechanisms by which this protein influences the viral
life cycle remain unclear.
In addition to agnoprotein function, the DNA of the agnogene
has been shown to contain 3 host cell factor binding sites. Deletion
of the agnogene DNA has a greater effect on replication than
prevention of agnoprotein expression by mutation of the start
codon [30]. In the agnogene deletion present in JCVCPN, 1 of the
3 sites is completely deleted, and a second is shortened by 1
nucleotide.
We hypothesized that the agnogene deletion of JCVCPN allowed
the virus to infect cortical pyramidal neurons. We used cell culture
models to study the replication of JCVCPN compared to the
prototype strain JCVMad-1 [31] in different cell types. We
generated chimeric viruses of JCVCPN and JCVMad-1, swapping
both the agnogene and RR, to determine the specific effects of the
agnogene deletion and the archetype-like RR on viral replication
in cell culture. In these experiments we characterized the
replication of JCVCPN in different cell types, and determined the
relative contributions of the agnogene deletion and archetype-like
RR to the JCVCPN replication phenotype. Studying these novel
naturally occurring changes in JCVCPN provided unique insights
into our understanding of the function of the agnogene and RR
form in JCV replication.
Materials and Methods
Cell Culture
Cos-7 [32], SVG [33] and IMR-32 [34] cells were purchased
from the ATCC. Cos-7 cells were maintained in Dulbecco’s
Modified Eagle Medium (DMEM) supplemented with 10% fetal
bovine serum (FBS), Penicillin (500 units/mL) and Streptomycin
(500 mg/mL). SVG cells were maintained in Minimum Essential
Medium (MEM) supplemented with Sodium Bicarbonate (1.5 g/
L), 10% FBS, Penicillin (500 units/mL) and Streptomycin
(500 mg/mL). IMR-32 cells were maintained in MEM supple-
mented with Sodium Bicarbonate (1.5 g/L), Sodium Pyruvate
(1 mM), Non-Essential Amino Acids (NEAA) (Invitrogen), 10%
FBS, Penicillin (500 units/mL) and Streptomycin (500 mg/mL).
Plasmids
Construction of the JCVCPN and JCVMad-1 plasmids was
previously described by Dang et al. [17]. To generate the
agnogene chimeric viruses Mad-1 C-Agno and CPN M-Agno,
the agnogene region was excised using the restriction enzymes
ApaI and PciI (New England Biolabs), and the digested DNA was
run on an agarose gel. The agnogene DNA and the virus minus
the agnogene DNA bands were excised and purified using the
QIAquick Gel Extraction Kit (QIAGEN). Agnogene DNA
segments were ligated into the viral backbone using T4 ligase
(New England Biolabs). The resulting plasmids were transformed
into TOP10 (Invitrogen) or XL1-Blue cells (Agilent). Plasmid
DNA was maxi prepped (QIAGEN), and plasmids were fully
sequenced. The RR chimeras were generated with the same
protocol, using the restriction enzymes BamHI and PciI (NEB) to
excise the RR. Mad-1 Pt and Mad-1 Del plasmids were previously
described [30], and obtained as a generous gift from Dr Safak.
The agnogene from these viruses was introduced into our JCVMad-
1 or JCVCPN plasmid using the ApaI and PciI restriction sites as
previously described.
Transfection
Full-length JCV genomes were digested out of the plasmid
backbone using EcoRI (NEB) and run on a 0.8% agarose gel. The
5 kb virus band was purified using the QIAquick Gel Extraction
Kit (QIAGEN). Cells were transfected with 1 mg (for IMR-32 and
SVG cells) or 2 mg (for Cos-7 cells) of purified JCV DNA using
FuGENE6 transfection reagent (Roche or Promega) in 6 well
plates. 3 days post-transfection, cells were passaged 1:3 to T25
flasks, and subsequently every 3–4 days 1:4 in T25 flasks. At each
passage, supernatant was collected and cells were collected,
pelleted and stored at 280uC until further analysis.
DNA Extraction and Quantitative PCR (QPCR)
DNA was extracted from cell pellets and supernatant samples
using the QIAamp DNA Blood Mini Kit (QIAGEN). QPCR was
performed as previously described [15]. An RNAase P primer/
probe set (Applied Biosystems) was used in a multiplex assay with
the JCV primer/probe set on cell lysate samples. Copies RNAse P
per reaction was determine and divided by 2 to determine the
number of input cells for each reaction. Copies JCV/cell was
calculated by dividing the copies JCV per reaction by the number
of cells per reaction. All samples were run in triplicate.
RNA Extraction and qRT-PCR
RNA was extracted using the RNEasy Mini Kit (QIAGEN).
RNA samples were digested with rDNAse I (Ambion) to remove
any contaminating DNA. Reverse transcription was done using
the High Capacity RNA-to-cDNA Kit (Applied Biosystems).
QPCR was performed on a 7300 Real-time PCR System using
Gene Expression Master Mix (Applied Biosystems). For amplifi-
cation of the early transcript mRNA, a primer probe set spanning
the Large T Ag splice site was used. The primers were JCT208F
(59-CATCAGCCTGATTTTGGTACATG-39, reverse comple-
ment of position 4784–4806) and JCT 279R (59-CCAG-
GATTCCCATTCATCTGTT-39, position 4392–4412). The
probe used was JCT-232p (6FAM-59-AAT AGT TCA GAG
GTG CCA AC-39-MGB, reverse complement of position 4419–
4426 and 4771–4482). For detection of late transcript mRNA we
used the primers JCVP1-745F (59-GGTGACAACTTA-
TACTTGTCAGCTGTT-39, position 2213–2239) and JCVP1-
812R (59-TGCTGGGAACCAGACCTGTT-39, reverse comple-
ment of position 2261–2280) and the probe JCVP1-773p (6FAM-
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59-ATG TCT GTG GCA TGT TTA-39-MGB, position 2241–
2248). A TATA-box binding protein (TBP) primer/probe set
(Invitrogen) was used as the endogenous control for determination
of relative quantity by the comparative CT method (also known as
the DDCt method) [35]. All samples were run in triplicate wells.
Western Blotting
Cells were lysed in TNN lysis buffer (50 mM Tris-HCl pH 7.5,
150 mM NaCl, 0.1% NP40) with 0.2 mM Na-Orthovanadate and
1% protease inhibitor cocktail for 30 minutes on ice. Samples were
centrifuged at 8000 rpm for 4 min to remove cell debris. Laemmli
Buffer (Bio-Rad) was added to whole cell lysate. Samples were
boiled for 10 min and run on a 10% SDS-PAGE gel in Tris/
Glycine/SDS running buffer (Bio-Rad). Samples were transferred
for 2 hours at 150 mAmps to a nitrocellose membrane in Transfer
Buffer (Tris/Glycine with 20% methanol) or to a nitrocellulose
membrane using the iBlot system (Invitrogen). Membranes were
blocked using 5% milk in PBST and incubated overnight at 4uC
with VP1 antibody pAB597 (1 mg/mL) diluted 1:1000 or loading
control anti-alpha tubulin [DM1A] (abcam) in 2% milk in PBST.
An HRP conjugated goat-anti mouse IgG secondary antibody
(Bio-Rad) was used and detection was done with ECL Plus reagent
(Thermo Scientific). Signal was detected on film.
Flow Cytometry Analysis of JCV-Positive Cells
Cells were trypsinized, collected and washed with 2% FBS in
PBS. Cells were passed through a 30 mm filter (Miltenyi Biotec)
and incubated for 20 minutes at 4uC with Aqua Amine to stain
dead cells, and then washed with PBS. Cells were fixed with
Cytofix/Cytoperm (BD Biosciences) for 20 minutes at 4uC then
washed with PBS. Staining with the primary antibody PAB597
(mouse monoclonal anti-VP1) in Perm/Wash Buffer (BD Biosci-
ences) was done for 2 hours at 4uC. Cells were washed with Perm/
Wash Buffer, then PBS and then stained with Alexa 488
conjugated Anti-Mouse IgG (Invitrogen) secondary antibody in
Perm/Wash Buffer for 1 hour at 4uC. Cells were washed, and
then analyzed using a BD LSR II Flow Cytometer (BD
Biosciences).
JCV Infectivity Test
Cos-7 cells were plated in 6 well plates at low density and
allowed to adhere overnight. Cell free supernatant collected from
transfected cells was put on the Cos-7 cells, and incubated 2 hours
at room temperature with rocking. Supernatant was not digested
with DNAse to remove free JCV DNA, as previous experiments
have shown that digesting with DNAse does not affect the levels of
JCV DNA detected in the supernatant by qPCR, or the
percentage of cells subsequently infected from the supernatant
(data not shown). The infection was allowed to proceed for 7 days.
Cells were then collected and analyzed for either VP1 expression
by flow cytometry or JCV DNA by QPCR as previously described.
Statistical Analyses
Analyses were done using SAS Software version 9.3. Data was
tested for normality before statistical analysis. P-values for DNA
levels were determined using the non-parametric Wilcoxon Rank
Test. P-values for mRNA levels were done using univariate
analysis, and taking the student’s t p value. Flow cytometry p-
values were determined using Student’s t test.
Results
JCVCPN has a 143 base pair deletion in the agnogene and
an archetype-like RR
The JCVCPN1 RR is archetype-like, lacking a duplication of the
TATA-box and containing a 66 bp and 80 bp insert, which
contain portions of the 23 bp and 66 bp inserts present in
archetype RR (Fig. 1A) [17]. A 143 bp deletion in the agnogene is
also present in JCVCPN1 (Fig. 1B) [17]. This deletion creates a
premature stop codon, and is predicted to code for a truncated 10
amino acid agnoprotein. Multiple forms of JCVCPN were
identified, including JCVCPN1.1 and JCVCPN1.2 which both
contain the same regulatory region and agnogene deletion. In
addition, JCVCPN1.2 contains a 75 bp duplication between the
agnogene and the VP2 gene, encompassing the start of the VP2
gene (Fig. 1B). This form is predicted to encode for both a
truncated and a full length VP2. Our studies determined that
JCVCPN1.1 and JCVCPN1.2 are phenotypically equivalent in our
cell cultures model (data not shown). Therefore, we chose to
conduct the experiments in this study using the JCVCPN1.2 strain,
because it was the predominant strain in the JCVE patient’s brain.
JCVCPN1.2 is referred to as JCVCPN for the remainder of this work.
JCVCPN can replicate DNA in cell culture, but at a lower
level than JCVMad-1
To determine the cellular tropism of JCVCPN, we studied its
replication in cell culture. We used multiple cell lines to model the
replication of the virus in three different types of cells, kidney cells,
glial cells and neurons. Cos-7 cells are African Green Monkey
kidney cells which express SV40 T Ag, and are known to replicate
JCV well [32]. SVG cells are human fetal glial cells, also
transformed with SV40 T Ag [33]. IMR-32 cells are a human
neuroblastoma cell line, derived from a tumor isolated from the
abdominal cavity of a child, which do not express any
polyomavirus T Ag [34]. We first wanted to determine if JCVCPN
is capable of genome replication. To do so, linearized genomes of
JCVCPN and JCVMad-1 were transfected into Cos-7, SVG and
IMR-32 cells. DNA from cell lysate, representing JCV DNA
replicated in the transfected cells, and supernatant, representing
DNA released from the transfected cells, was extracted and
digested with DpnI to remove any remaining input plasmid DNA.
JCV genome copy number was determined by QPCR. We found
that JCVCPN replicated DNA after transfection in all 3 cell lines
tested (Fig. 1C–H). However, the levels of DNA were not
equivalent to those seen with the prototype strain JCVMad-1.
In Cos-7 kidney cells, JCVMad-1 establishes a high level infection
that persists over 3 weeks, as measured by copies JCV DNA in the
cell lysate and supernatant (Fig. 1C and 1D). JCVCPN has
equivalently high levels of JCV genomes present in the cell lysate
and supernatant during the first week post-transfection, but does
not maintain such a high viral load, with the copy number
decreasing with time. In SVG glial cells, both JCVMad-1 and
JCVCPN establish persistent infections (Fig 1E and 1F). Levels of
JCVCPN genome copies in cell lysate and supernatant at later time
points post-transfection are significantly lower than those of
JCVMad-1, but with a smaller magnitude of difference than
observed in Cos-7 cells. In IMR-32 neuronal cells, JCVMad-1 DNA
decreased over the first 2 weeks after transfection, and then leveled
off, remaining detectable over 3 weeks (Fig. 1G and 1H). In
contrast, JCVCPN decreased and dropped below the limit of
detection at 14 days post-transfection in cell lysate and 17 days
post-transfection in the supernatant. These results indicate that
JCVCPN is able to replicate its genome after transfection into Cos-
7, SVG and IMR-32 cells, but may have a decreased capacity to
A Novel JC Virus Isolate with an Agnogene Deletion
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persist and spread within the culture compared to prototype
JCVMad-1. Additionally, JCVCPN does not display a replication
advantage in the neuronal cell culture line tested.
JCVCPN expresses both early and late transcripts, but at
decreased levels compared to JCVMad-1
Knowing that JCVCPN is able to replicate viral DNA, but not
establish a persistent high level infection, we wanted to determine
if JCVCPN is able initiate transcription of mRNAs from the early
and late promoters. To do so, we used qRT-PCR on RNA from
transfected cells using primer and probe sets located in T Ag to
detect early transcripts, and in VP1 to detect late transcripts. In
Cos-7, SVG and IMR-32 cells, JCVCPN expresses detectable levels
of both the early and late transcripts (Fig. 2). In Cos-7 cells, the
level of early transcripts is significantly lower than those seen with
JCVMad-1 3 and 10 days post-transfection (Fig. 2A). In SVG cells,
Figure 1. JCVCPN replicates viral DNA, but at lower levels than JCVMad-1. (A) JCVCPN RR is archetype-like (adapted from (17)). (B) JCVCPN1.2
(hereafter referred to as simply JCVCPN) agnogene contains a 143 base pair deletion followed by a 75 base pair duplication at the beginning of the
VP2 gene. (C–H) Cos-7, SVG and IMR-32 cells were transfected with linearized JCV genomes, or mock transfected. Cells were subcultured every 3–4
days and cell and supernatant samples were collected. DNA was extracted from the samples, digested with DpnI to remove input plasmid DNA, and
analyzed by QPCR. Data represents the average of 4–10 independent experiments. In Cos-7 cell lysate (C) and supernatant (D) JCVMad-1 but not
JCVCPN establishes a persistent infection. In SVG cell lysate (E) and supernatant (F) JCVMad-1 and JCVCPN both establish persistent infections. In IMR-32
cells, JCVMad-1 infection persists for 21 days, while JCVCPN becomes undetectable in cell lysate (G) and in supernatant (H). Error bars represent standard
deviation. P-values were calculated using the Wilcoxon Rank Test. ND is not detected.
doi:10.1371/journal.pone.0080840.g001
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the level of early transcripts is similar between JCVCPN and
JCVMad-1 3 and 7 days post-transfection, and significantly lower 10
days post-transfection (Fig. 2B). In IMR-32 cells, level of early
transcripts produced by JCVCPN is significantly lower than those of
JCVMad-1 at 3, 7 and 10 days post-transfection (Fig. 2C). In all
three cell lines, the level of late transcripts is markedly lower in
JCVCPN transfected cells compared to JCVMad-1 transfected cells
(Fig. 2D–F). These results indicate that, although both the early
and late promoter of JCVCPN are transcriptionally active, they
function at a level lower than JCVMad-1. The decrease in transcript
levels is larger for the late than the early promoter.
JCVCPN fails to produce detectable levels of VP1 protein
in Cos-7 cells
We then wanted to determine if JCVCPN produces VP1 protein
from the late mRNA. JCVMad-1 transfected cells produce VP1
protein, with the amount of VP1 present increasing with later
times post-transfection (Fig. 2G). JCVCPN does not produce
detectable levels of VP1 protein, even with long exposure times
(Fig. 2G).
To determine if there is VP1 present in a small number of
JCVCPN transfected cells, which cannot be detected by Western
Blot, we developed a protocol to analyze transfected Cos-7 cells for
VP1 expression using flow cytometry. JCVMad-1 transfected cells
were positive for VP1 expression, with an increase in the
percentage of cells positive for VP1 over time, with the highest
percentage of VP1 positive cells seen 21 days post-transfection
(Fig. 2H). The percentage of JCVMad-1 VP1 positive cells is
significantly higher than the background observed in Mock
transfected cells. JCVCPN transfected cells are not positive for
VP1 by flow cytometry at a level significantly higher than Mock
transfected cells (Fig 2H). This supports the results seen in using
Western blotting, that JCVCPN does not express detectable levels
of VP1 protein.
JCVCPN produces low levels of infectious virions
Although we could not detect VP1 expression by Western Blot
or flow cytometry in transfected cells, there may be a very low level
of expression below our limit of detection. We therefore wanted to
determine if JCVCPN transfected cells are producing virions
capable of infecting a new round of cells. To do so, supernatant
Figure 2. JCVCPN expresses less early and late mRNA and VP1 protein than JCVMad-1. (A–F) Cos-7, SVG and IMR-32 cells were transfected
with JCVMad-1, JCVCPN or mock transfected and samples collected as described in Figure 1. qRT-PCR was used to determine the levels of early (T Ag)
and late (VP1) transcripts. Relative Quantity (RQ) was calculated using the DDCt method, using TATA-Box Binding Protein (TBP) as the endogenous
control and JCVMad-1 as the calibrator sample. Data represents the average of 5–6 independent experiments. (A and D) In Cos-7 cells, JCVCPN expresses
significantly lower levels of T Ag (A) and VP1 (D) mRNA. (B and E) In SVG cells, levels of T Ag (B) mRNA expressed by JCVCPN are similar to JCVMad-1,
while VP1 (E) mRNA is significantly lower. (C and F) JCVCPN expresses significantly less T Ag (C) and VP1 (F) mRNA in IMR-32 cells. Error Bars represent
standard deviation. P values were calculated for Student’s t test using univariate analysis. ND is not detected. (G) Western blots were done with
PAB597 (anti-VP1) using cell lysate from Cos-7 cells transfected with either JCVMad-1 (Lanes 1–3), JCVCPN (Lanes 7–9) or mock transfected cells (Lanes
4–6) collected 7 (Lanes1,4,7), 14 (Lanes 2,5,8) or 21 (Lanes 3,6,9) days post-transfection. VP1 can be detected in JCVMad-1 transfected cells at all time
points, but not at any time with JCVCPN, with either a short (upper panel) or long (middle panel) exposure. Anti-tubulin antibody was used for loading
control (lower panel). Blots are representative of 3 independent experiments (H) JCVMad-1, JCVCPN or mock transfected Cos-7 cells were analyzed for
VP1 expression by flow cytometry. JCVMad-1 but not JCVCPN transfected cells have significantly higher levels of VP1 positive cells than Mock
transfected samples. Results are the average of 4 independent experiments. Error bars represent standard deviation. P values were calculated using
students t test, comparing JCVMad-1 and JCVCPN to mock.
doi:10.1371/journal.pone.0080840.g002
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was collected from transfected Cos-7, SVG and IMR-32 cells 7, 14
and 21 days post-transfection and was used to infect Cos-7 cells.
Infection was allowed to proceed for 7 days. Cells were collected,
and analyzed for JCV DNA by QPCR or stained for VP1 and
analyzed by flow cytometry.
JCVMad-1 containing supernatant from Cos-7 cells was able to
establish an infection in the new cells, with the viral load and the
percentage of cells infected increasing with supernatant collected
at later time points post-transfection (Fig. 3A and B). The
percentage of VP1 positive cells was significantly higher than in
the samples treated with supernatant from mock transfected cells
(Fig. 3B). In contrast, cells infected with JCVCPN containing
supernatant had significantly lower levels of viral DNA detected,
which decreased over time, becoming undetectable in samples
infected with supernatant collected 21 days post transfection
(Fig. 3A). The percentage of JCVCPN VP1 positive cells was not
significantly higher than observed with Mock supernatant (Fig. 3B),
which is most likely due to the lack of detectable expression of VP1
protein in JCVCPN transfected cells.
Similar results were seen using supernatant from transfected
SVG and IMR-32 cells, with low levels JCV DNA detected in cells
infected with JCVCPN containing supernatant collected 7 days
post-transfection, and then decreasing (Fig. 3C and D). Using
supernatant from SVG cells, JCVCPN DNA remains detectable
with supernatant collected 14, but not 21, days post-transfection
and JCVMad-1 infected cells had DNA levels that were significantly
higher than those observed with JCVCPN at all time points
(Fig. 3C). In contrast to the results observed using Cos-7
supernatant, the viral loads in JCVMad-1 infected cells decreased
with later collection points using SVG supernatant (Fig. 3C). Cells
infected with supernatant collected 14 and 21 days post-
transfection from IMR-32 cells had undetectable JCVCPN DNA
levels (Fig. 3D). JCVMad-1 DNA was detected in cells infected with
supernatant collected from IMR-32 cells at 7 and 21 days, but not
14 days, post-transfection (Fig. 3D). This is most likely due to the
levels of JCV DNA being below the limit of detection of our assay.
Generation of chimeras and agnogene mutants
The results of the above experiments comparing JCVCPN and
JCVMad-1 suggest that JCVCPN has a block preventing late gene
expression and protein production, as well as in the production
and release of infectious virions. The two major regions of
difference between JCVCPN and JCVMad-1 are the RR and the
agnogene. To determine which area of the virus is the major
contributor to the phenotype of JCVCPN, we generated chimeric
viruses of JCVCPN and JCVMad-1 (Fig. 4). We swapped the
agnogene genes of the two viruses to generate Mad-1 C-Agno and
CPN M-Agno. Mad-1 C-RR and CPN M-RR were generated by
exchanging the RRs of the two viruses. We obtained two agno
deletion mutations, Mad-1 Pt, which has a start codon point
mutation which prevents the expression of agnoprotein, and Mad-
1 Del, which has the entire agnogene deleted. CPN M-Pt contains
the full length agnogene with the start codon point mutation from
Figure 3. JCVCPN transfected IMR-32, SVG and Cos-7 cells produce low levels of infectious virions. Supernatant from transfected Cos-7,
SVG and IMR-32 cells was collected 7, 14 and 21 days post-transfection, and used to infect naive Cos-7 cells. At 7 days post-infection, cells were
collected and either analyzed for JCV DNA using QPCR (A, C and D) or stained for VP1 and analyzed using flow cytometry (B). Supernatant collected 7
days post-transfection from JCVCPN transfected Cos-7 (A), SVG (C) or IMR-32 (D) cells can establish an infection in naı¨ve Cos-7 cells, as measured by the
presence of JCV DNA 7 days post-infection. Levels of DNA detected with JCVCPN infection are significantly lower than with JCVMad-1 infection (A, C and
D). (B) VP1 positive cells are detected after infection with JCVMad-1, but not JCVCPN containing supernatant. Data is the average of 3–4 independent
experiments. Error bars represent standard deviation. P vales were calculated using Wilcoxon rank test for QPCR data, comparing JCVCPN to JCVMad-1.
P-values for flow cytometry data were calculated using students t test, comparing JCVMad-1 and JCVCPN to mock at each time point. ND is not
detected.
doi:10.1371/journal.pone.0080840.g003
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Mad-1 Pt. We studied these additional mutants in Cos-7 cells,
because these cells displayed the greatest difference in phenotype
between JCVMad-1 and JCVCPN.
The agnogene deletion is the major contributor to the
phenotype of JCVCPN
To begin characterizing the phenotypes of the viruses shown in
Figure 4, linearized DNA was transfected into Cos-7 cells, and
JCV DNA levels in cell lysate and supernatant were monitored for
3 weeks using QPCR (Fig. 5). Mad-1 C-Agno has significantly
lower levels of DNA from 10–21 days post-transfection compared
to Mad-1, while Mad-1 C-RR has DNA levels similar to Mad-1
(Fig. 5A and 5C). This indicates that introducing the agnogene
deletion of JCVCPN into Mad-1 results in a decrease in DNA
replication. In contrast, the introduction of the JCVCPN RR does
not. This suggests that the major cause of the replication kinetics
seen with JCVCPN are due to the agnogene deletion, and the not
the archetype-like RR. When comparing the agno deletion viruses
to JCVMad-1, Mad-1 Pt has similar DNA levels, while Mad-1 Del
had decreased levels late in infection similar to JCVCPN (Fig. 5A
and 5C). This provides evidence the gene deletion is more
important than the loss of the agnoprotein for the observed
phenotype.
Furthermore, the results seen with the viruses on the JCVCPN
backbone support these conclusions. CPN M-Agno, with the full
length agnogene and agnoprotein, and CPN M-Pt, with just a full
length agnogene, have the greatest increase of JCV DNA levels
compare to JCVCPN, and in both cases the level of DNA increase
is similar (Fig. 5B and 5D). This supports the conclusion that the
deletion in the agnogene causes the decreased replication ability of
JCVCPN. CPN M-RR, with the JCVMad-1 RR, also show some
increase in DNA levels, but to a lesser extent than CPN M-Agno
(Fig. 5B and 5D).
Deletion in the agnogene prevents expression of VP1
protein
We then sought to determine if the levels of VP1 protein
expression would correspond with levels of viral DNA in cells
transfected with the chimeras and agno deletion mutants. Western
blots were done for VP1 expression in JCV transfected Cos-7 cells.
At 14 days post-transfection, only JCVMad-1, Mad-1 Pt, Mad-1 C-
RR and CPN M-Agno have detectable levels of VP1 (Fig. 6A). At
21 days post-transfection, all of these viruses and CPN M-Pt have
detectable VP1 protein expression (Fig. 6B). All of these viruses
have full length agnogenes, but Mad-1 Pt does not have
agnoprotein expression. Compared to JCVMad-1, Mad-1 Pt shows
some decrease in VP1 expression, while Mad-1 Del has a complete
lack of VP1 expression. All of the viruses with the JCVCPN
agnogene deletion, JCVCPN, Mad-1 C-Agno and CPN M-RR lack
VP1 expression (Fig. 6A and 6B). Taken together, these results
indicate that the deletion in the agnogene results in decreased or
undetectable levels of VP1 protein expression, and that the levels
of DNA replication correspond with the presence of VP1 protein
expression.
Deletions in the agnogene reduce the production of
infectious virions
Finally, we sought to determine if the ability to produce
infectious virions of the chimeric and agno deletion viruses also
corresponds with DNA levels and VP1 protein production in these
cells. Supernatant collected from Cos-7 cells 21 days post-
transfection was used to infect naı¨ve Cos-7 cells, and the DNA
levels (Fig. 7A) and percentage of cells expressing VP1 (Fig. 7B)
were determined by QPCR and flow cytometry, respectively, at
day 7. Compared to JCVMad-1-infected cells, both Mad-1 C-agno
and Mad-1 Del –infected cells have significantly lower viral loads,
showing a 1.5–2 log decrease (Fig. 7A). Mad-1 Pt and Mad-1 C-
RR-infected cells also have significantly lower viral loads than
JCVMad-1-infected cells, but tended to have a smaller magnitude of
decrease (Fig. 7A). Mad-1 C-agno and Mad-1 Del-infected cells
have significantly lower percentages of cells expressing VP1, while
Mad-1 Pt and Mad-1 C-RR-infected cells do not (Fig. 7B). CPN
M-Agno, CPN M-RR and CPN M-Pt-infected cells all have
detectable DNA levels, with significantly higher viral loads
compared to JCVCPN (Fig. 7A). Compared with JCV CPN-infected
cells, CPN M-Agno-infected cells have a significantly higher
percentage cells expressing VP1, and CPN M-Pt-infected cells
tended to have more cells expressing VP1. Interestingly,
introduction of only the full length gene without protein expression
in CPN M-Pt is enough to rescue the DNA levels, and show some
increase in percent of cells expressing VP1.
The results of these infection experiments suggest that the
deletion in the agnogene is the primary cause of the phenotype
observed with JCVCPN. However, CPN M-RR, with the JCVMad-1
RR does show some increase in DNA replication and production
of infectious virions compare to JCVCPN, which may indicate that
the RR composition is also affecting replication of the virus, but to
a lesser degree than the agnogene deletion. It is likely that the
combination of the agnogene deletion together with archetype-like
RR is the cause of the overall phenotype of JCVCPN. Overall,
these experiments have used the unique naturally occurring
JCVCPN agnogene deletion and archetype-like RR to clarify the
Figure 4. JCVMad-1 and JCVCPN chimeras and agno deletion
mutants. This diagram shows the various chimeric viruses and deletion
mutants generated. Black represents sequences from JCVMad-1 and
white represents sequences from JCVCPN. Lines represent DNA
sequences. Dotted Lines represent deletions. Boxes represent genes.
An X through ATG represents mutation of the start codon to eliminate
protein expression. Mad-1 C-Agno is JCVMad-1 with the JCVCPN
agnogene introduced. CPN M-Agno is JCVCPN with a full length
agnogene from JCVMad-1 introduced. Mad-1 C-RR is JCVMad-1 with the
JCVCPN RR and CPN M-RR is JCVCPN with the JCVMad-1 RR. Mad-1 Pt is
JCVMad-1 with a mutated start codon which prevents the expression of
the agnoprotein and Mad-1 Del is JCVMad-1 with the entire agnogene
deleted. CPN M-Pt is JCVCPN with the agnogene of Mad-1 Pt.
doi:10.1371/journal.pone.0080840.g004
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role of the agnogene and RR forms in JCV replication in cell
culture.
Discussion
JCVCPN was isolated from the brain of the first patient to be
diagnosed with JCVE, a novel syndrome characterized by
infection of cortical pyramidal neurons. JCVCPN is the first
naturally occurring isolate with a large deletion in the agnogene,
which was originally called agno due to the unknown nature of its
function. While studies have begun to shed light on the function of
the agnoprotein and agnogene, there is still much to be learned.
JCVCPN presents the opportunity to study the function of the
agnogene and agnoprotein in a naturally occurring pathogenic
variant of JCV, isolated in association with infection of a new cell
type.
In this study, we compared the replication of JCVCPN to that of
the prototype virus JCVMad-1. We used Cos-7 cells to model
infection in kidney cells and SVG cells as a glial cell model. Both of
these cell lines are widely used to study the replication of JCV in
kidney and glial cells, and it is commonly thought that the results
obtained in them are applicable to what would occur in these cell
types during JCV infection in humans. Studying the replication of
JCV in cortical pyramidal neurons is challenging, as there are no
cortical pyramidal neuron cell lines available. We therefore used
IMR-32 neuroblastoma cells to model neuronal infection. Using
these cell lines allowed us to study the replication of JCVCPN in
Figure 5. The agnogene deletion of JCVCPN is the primary cause of its replication defect. Linearized JCV DNA of JCVMad-1, Mad-1 C-Agno,
Mad-1 C-RR, Mad-1 Pt, Mad-1 Del, JCVCPN, CPN M-Agno, CPN M-RR, and CPN M-Pt were transfected into Cos-7 cells and DNA levels were quantified
over 3 weeks, as described in Figure 1. (A and C) Levels of DNA with JCVMad-1 and the chimeras and agno deletion viruses on the JCVMad-1 backbone
were measured in the cell lysate (A) and supernatant (C). Mad-1 C-Agno and Mad-1 Del show significantly lower levels of DNA late in infection. (B and
D) Levels of DNA with JCVCPN and the chimeras and agno deletion viruses on the JCVCPN backbone were measured in the cell lysate (B) and
supernatant (D). Introduction of a full length agnogene causes the greatest increase in DNA levels. Data represents the average of 4–10 independent
experiments. Error bars represent standard deviation. P-values were calculated with the Wilcoxon Rank Test. ND is not detected.
doi:10.1371/journal.pone.0080840.g005
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different cell types in cell culture. We found that JCVCPN was
capable of replicating its genome in cell culture. However, it could
not establish an infection at the same level observed with JCVMad-1
over time and did not display any replication advantage over
JCVMad-1 in any cell line. Levels of JCVCPN DNA replication in
Cos-7 and IMR-32 cells were similar to JCVMad-1 at early time
points, and then decreased at later time points, indicating that the
virus is able to replicate viral DNA after transfection but the
infection could not spread and persist in the cell culture at the
same level as JCVMad-1. In addition, mRNA and VP1 protein
analyses showed some decrease in early transcription and a
marked decrease in late transcription, with no detectable VP1
protein production. In all three cell lines, low levels of infection
were observed using supernatant from JCVCPN transfected cells,
but only using supernatant collected at early times post-transfec-
tion, and at levels significantly lower than seen with JCVMad-1.
These data indicate that the virus has a block in late gene
expression and protein production, which results in low levels of
infectious virions being released, and an inability to sustain a
persistent high level infection in cell culture. Furthermore, since
agnoprotein has been implicated in late stages of viral maturation,
there may be an additional block at the level of virion formation
and/or release independent of the lack of VP1 production.
JCVCPN and JCVMad-1 are different in two regions, the RR and
the agnogene. This provided us with the unique opportunity to
determine for the first time how each of these regions contributed
to the phenotype of JCVCPN. We therefore studied a series of
chimeric viruses of the RR and agnogene. Interestingly, the
agnogene deletion in JCVCPN was the predominant cause of its
phenotype, not the archetype-like RR. Moreover, the loss of the
agnogene DNA had a larger effect on the replication of the virus
than the loss of agnoprotein expression. Finally, the archetype-like
RR also showed a detrimental effect on JCVCPN replication, but of
a smaller magnitude than that of the agnogene deletion. For these
experiments we used Cos-7 cells, because they displayed the
largest difference in phenotype between JCVCPN and JCVMad-1
and allowed us to use the greatest number of techniques to study
these viruses. We believe that the results obtained in these
experiments are representative of what would be observed with the
other cell lines used in this study.
Previous studies have implied that agnoprotein had a role in
viral DNA replication [23,24]. However, JCVCPN is able to
Figure 6. Deletion in the agnogene prevents VP1 expression. Western blots for VP1 were done as described in Figure 2. (A) VP1 levels in Cos-
7 cell lysate 14 days post-transfection. (B) VP1 levels in Cos-7 cells 21 days post-transfection. Levels of VP1 expression are drastically reduced in Mad-1
C-Agno, and expression is rescued by the full length agnogene in CPN M-Agno. Deletion of the agnogene Mad-1 Del results in a greater decrease in
VP1 expression than just the prevention of the protein expression in Mad-1 Pt. Blots are representative of 3 or 4 independent experiments.
doi:10.1371/journal.pone.0080840.g006
Figure 7. Loss of the agnogene results in decreased production of infectious virions. Supernatant was collected from Cos-7 cells 21 days
post-transfection and used to infect naive Cos-7 cells. After 7 days, the cells were analyzed for (A) JCV DNA by QPCR or (B) VP1 expression by flow
cytometry. Deletions in the agnogene in JCVMad-1-infected cells resulted in a significant decrease in JCV genomes/cell and percentage of cells
expressing VP1, while introduction of a full length agnogene into JCVCPN results in a significant increase in the viral load and percentage of cells
expressing VP1. Data is the average of 3 independent experiments. Error bars represent standard deviation. P values were calculated using Wilcoxon
rank test for QPCR data, comparing each virus to its parent virus, either JCVMad-1 or JCVCPN. P-vales for flow cytometry data were calculated using
students t test using the same sets of comparisons. ND is not detected.
doi:10.1371/journal.pone.0080840.g007
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produce levels of DNA similar to JCVMad-1 early after transfection,
with DNA levels decreasing with time. These results suggest that
an agnogene-deletion mutant can indeed replicate DNA, but levels
drop off due to blocks at later steps in infection, thereby preventing
spread within the cell culture. Conflicting studies have associated
agnoprotein with gene expression, with both the loss of
agnoprotein [19,30] or its presence [23,26] suppressing activity
of the late promoter of JCV in different experimental systems.
Additionally, deletion of the full agnogene causes a greater
decrease in VP1 expression than prevention of agnoprotein
expression without deletion of the agnogene DNA [30]. Our data
shows that the deletion in the agnogene of JCVCPN results in a
block in late gene expression, impairing the release of virions
capable of infecting new cells and propagating the infection in cell
culture. This is consistent with the results of Akan et al [30] and
highlights the importance of the agnogene DNA in addition to the
protein it codes for. Further studies are needed to determine the
mechanism of the block in VP1 expression. One possibility is that
a host cell factor which binds to one of the sites in the agnogene,
identified by Akan et al [30], is involved in expression of the late
transcript. Further investigations to identify these cellular proteins
are warranted to determine the mechanism by which they act
during JCV replication. Another potential mechanism is that
deletions in the agnogene somehow alter the splicing or translation
of VP1 from the late mRNA.
Previous studies of JCV deletion mutants lacking agnoprotein
expression have implicated the agnoprotein in genome packaging
and/or virion formation and release, with empty capsids being
produced by viruses lacking the agnoprotein [27,28]. In our study
however, the agnoprotein start codon point mutant was able to
replicate its DNA and produce infectious virions at a level similar
to JCVMad-1in Cos-7 cells, which suggests that at least in these
cells, the agnoprotein is not necessary for formation and release of
virions containing viral genomes.
Archetype RR is typically found in the urine, but the JCVCPN
RR isolated from the brain of the JCVE patient is archetype-like.
Studies of the replication of different forms of RR have shown that
archetype RR form has less active early and late promoters [36].
Surprisingly, our study did not find the archetype-like RR of
JCVCPN to be the primary cause of the decreased levels of late
transcription and VP1 protein expression. Introducing the
archetype-like RR of JCVCPN into JCVMad-1 had little effect on
the ability of the virus to replicate. JCVMad-1 RR introduced into
JCVCPN partially rescues replication, but had a lesser impact than
introduction of a full length agnogene. In fact the archetype-like
RR only has a significant impact on the virus once it has already
been impaired by a deletion in the agnogene, indicating that not
all archetype-like RR forms found in nature lead to lower levels of
viral replication.
While JCVCPN was unable to establish a persistent infection in
our cell culture model, it was found at high levels in the brain of
the JCVE patient. JCVCPN does produce some infectious virions in
cell culture, but at much lower levels than JCVMad-1. This does
not, however, mean that the virus was unable to establish an
infection in the brain of the JCVE patient. There are limitations to
the cell culture model we utilized in this study. First, the infection
in a person can take place on the timescale of years to decades,
while our experiments were done over weeks. Second, this
individual was also infected with a strain of JCV with a full length
agnogene and agnoprotein, which may have influenced the
replication of JCVCPN. Third, it may be that having low levels
of replication in the brain was actually advantageous to the virus
while faced with a healthy immune system, allowing it to
accumulate until the immune system became compromised and
JCVE developed.
After observing the infection of granule cell neurons in JCV
GCN and cortical pyramidal neurons in JCVE, we conducted
studies to determine if infection of neurons by JCV was limited to
these syndromes, or if it is more widespread. Based on staining of
PML brain samples, it is predicted that up to 51% of patients have
granule cell neurons infected by JCV [37]. Additionally, infection
of cortical neurons by JCV in classic PML cases has been observed
with infection present in the gray white junction and gray matter
[38]. These studies demonstrate that infection of neurons occurs in
a large number of PML patients, and is not limited to patients with
JCV GCN or JCVE. Further studies of the molecular composition
of JCV in neurons of patients with classic PML are needed to
determine whether these cells are also infected by JCV-deletion
mutants.
The study of unique pathogenic isolates of JCV, such as
JCVCPN or JCVGCN allows us to decipher the basic biology of JCV
replication using mutations that have arisen naturally during
infection in humans. Our studies of JCVCPN have provided
valuable insights into both the function of the agnogene and
agnoprotein, as well as a naturally occurring variation of the
regulatory region, on JCV replication. Our results have helped
clarify the role of the agnogene and agnoprotein in DNA
replication, transcription and protein expression, demonstrating
that a deletion in the agnogene has a dramatic effect on the
expression of VP1 protein and the production of infectious virions.
Further studies of naturally occurring variants of JCV will
continue to add clarity to our understanding of the biology of
JCV replication and pathogenesis.
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